Capricorn Scientific's Pipeline

CHO Fed-Batch Projects

Recombinant manufacturing of biopharmaceutical proteins in Chinese Hamster Ovary (CHO) cells has evolved into a powerful technique over recent decades, particularly in the production of monoclonal antibodies and other therapeutic proteins. From various CHO-related production platforms and systems, classical CHO fed-batch expression systems remain the gold standard in commercial biopharmaceutical production.

These systems enable the highest protein yields within short time periods of about 14 to 20 days by typically using stable CHO cell lines. As during fed-batch production, the medium is not exchanged and only feeding supplements and additives, such as glucose, are added to the cultures. Therefore, perfectly balanced fed-batch media and feeds, as well as optimized production systems, are crucial for successful commercial production.

Below, you will find examples of customers who successfully began their journey to commercial production by using Capricorn Scientific's CHO Media and Feeds in fed-batch production.

CHO Perfusion Projects

In addition to common fed-batch systems, CHO perfusion systems have been used for nearly two decades to produce biopharmaceuticals. Compared to fed-batch systems, which require large installations and space, perfusion expression achieves higher cell densities and higher space–time yields (STY), allowing the use of smaller bioreactors equipped with single-use systems.

Due to the extended production periods, perfusion systems are the method of choice for complex, difficult-to-produce proteins. Consequently, perfusion has become a preferred method for increasing the output of more stable therapeutic proteins, such as monoclonal antibodies, compared to traditional fed-batch operations. Perfusion media must support high viable cell densities and maintain cultures over extended durations of 30 days or longer.

Capricorn Scientific’s CHO Perfusion Media have already been successfully used to produce a variety of biopharmaceuticals.

HEK Fed-Batch Projects

HEK293 cells are the preferred expression host for recombinant protein production, where human-like glycosylation is crucial. Derivatives such as HEK293T serve as a robust platform for generating adeno-associated viruses (AAV) and lentiviruses, which are commonly used in gene therapy applications.

Due to the high transfection efficiency of HEK293 cells and the various methods for manipulating them, transient expression is a commonly utilized approach for high-yield production. Transient expression in systems with HEK293 cells bypasses the need for time-consuming cloning and clone-specific process optimization. In contrast, also stable HEK expression in fed-batch systems is commonly performed for pharmaceutical antibody production. 

Our HEK Media and Feeds have been used in various clinical trials for viral vector and protein production.